Science ❯ Medical Research ❯ Clinical Trials

Patient Outcomes

Vision Improvement Nephrotic Syndrome Behavioral Science Relapse Prevention Cancer Survival Rates Maturation Techniques Visual Rehabilitation Health Innovations Biological Mapping Health Technology Assessment Stem Cell Transplant Geographic Atrophy Disease Progression Health Equity

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

The decision is based on a 108-week study where the drug beat irbesartan, giving a new option for a rare kidney disease.

Slow Tapering With Therapy Matches Staying on Antidepressants, Major Review Finds

AI Analyzes Full Medical Records to Personalize Anticoagulant Use in Atrial Fibrillation